Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view

References

• Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):429S-56S
   Web of Science ®Google Scholar
• Marinigh R, Lip GY, Fiotti N, et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 2010;56:827-37
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142-7
   PubMed Web of Science ®Google Scholar
• Limone BL, Baker WL, Kluger J, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One 2013;8:e62183
   Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. JACC 2014;64:e1-76
   Google Scholar
• Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation 1999;99:3028-35
   PubMed Web of Science ®Google Scholar
• HalperinJL, HuismanM, DienerHC, et al. Patterns of newly detected atrial fibrillation and antithrombotic treatment in North America (GLORIA™-AF Phase II). American College of Cardiology 64th Annual Scientific Session in San Diego, CA, March 16, 2015
   Google Scholar
• Harburger JM, Aronow WS. Newer anticoagulants for non-valvular atrial fibrillation. Pharmaceuticals (Basel) 2012;5:469-80
   PubMedGoogle Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57. doi:10.1001/archinte.1994.00420130036007.
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-107
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hess GP. Abstract 258: Dabigatran etexilate is associated with shorter hospital length of stay and lower hospital costs compared to warfarin in treatment-naive, newly-diagnosed non-valvular atrial fibrillation patients. Circ Cardiovasc Qual Outcomes 2013;6:A258
   Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645-53
   PubMed Web of Science ®Google Scholar
• Farr A, Jung Y, Johnston S. Comparison of hospital length of stay between non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Chicago, IL: American Heart Association, 2014. pp 15-19
   Google Scholar
• Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med 2014;127:1075-82
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user‐friendly score (HAS‐BLED) to assess 1‐year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100
   PubMed Web of Science ®Google Scholar
• European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983a;70:41-55
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-8
   Web of Science ®Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-matched samples. Stat Med 2009;28:3083-107
   PubMed Web of Science ®Google Scholar
• Farr AM, Jing Y, Johnston S, et al. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Hosp Pract 2015;43:172-9
   Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:1521-8
   PubMed Web of Science ®Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered rivaroxaban versus warfarin with and without pretreatment parenteral anticoagulant therapies. Hosp Pract 2014;42:17-25
   Google Scholar
• Laliberté F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with non-valvular atrial fibrillation patients: an observational study from a cohort of matched users. Clin Ther 2015;37:554-62
   PubMed Web of Science ®Google Scholar
• Laliberté F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on health care costs among non-valvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther 2015;32:216-27
   PubMed Web of Science ®Google Scholar
• Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health 2013;16:498-506
   PubMed Web of Science ®Google Scholar
• Canestaro WJ, Patrick AR, Avorn J, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes 2013;6:724-31
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 2012;15:776-85
   PubMedGoogle Scholar
• Harrington AR, Armstrong EP, Nolan PE, Jr., et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81
   PubMed Web of Science ®Google Scholar
• Lip GY, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther 2014;36:192-210
   PubMed Web of Science ®Google Scholar
• Wisløff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics 2014;32:601-12
   PubMed Web of Science ®Google Scholar
• Amin A, Stokes M, Wu N, et al. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation. J Med Econ 2013;16:1193-202
   PubMedGoogle Scholar